ERES $6,98 daily and weekly charts by AF -- 19 August 2010 -- LINK BACK FOR OVER 700 CHARTS
eResearchTechnology, Inc. (NASDAQ: ERES) specializes in providing technology and services to collect, interpret and distribute cardiac safety and clinical data to pharmaceutical, biotech, medical device makers, clinical trial sponsors and contract research organizations (CROs) around the world. ERES’s solutions provide a centralized process for the collection and standardization of quality ECG data, which reduces inconsistencies that may occur from site to site, and also reduces their clients’ manpower, lowering costs and improving efficiencies. The company has been in business since 1977, and has participated in more than 5,000 studies, observing around 605,000 subjects/patients in more than 85 countries, over six continents.
Overall, ERES’ financials look very healthy. The company’s five-year sales growth rate of 15% is twice that of its competition; and its margins far surpass its peers. Moreover, ERES has no debt. That gives the company tremendous flexibility for growing internally and by acquisition. During the first six months of 2009, the company repurchased shares to the tune of some 2.6 million. That means more earnings shared by fewer investors—and that’s a big positive for owners of ERES. Over the years the company has proven to be an earnings winner, even during the very tough recession, and now that the economy is starting to come around, look for renewed upside in the stock.
Market Data 
Markets 
AI
